EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
Sandoz is one such company that hopes to offer the NHS savings potential. Its Humira biosimilar, Hyrimoz, could represent savings of more than £250 million a year, according to the company ...
The company ranks number one in biosimilars globally and across key markets in Europe. The commercial availability of Pyzchiva, which builds on the US launch of Hyrimoz in July 2023, marks an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback